DGIdb - METHOTREXATE Drug Record

METHOTREXATE chembl:CHEMBL34259 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MAXTREX
RASUVO
EMTEXATE PF
METOJECT
R-METHOTREXATE
MEXATE-AQ
ABITREXATE
R-9985
METHYLAMINOPTERIN
NSC-740
OTREXUP PFS
TCMDC-125488
TCMDC-123832
AMETHOPTERIN
EMT-25299
RHEUMATREX
OTREXUP
TCMDC-125858
EMTEXATE HIGH-POT
MEXATE
EBETREX
METHOTREXATE
TREXALL
ZLATAL
FOLEX
CL-14377
METOTREXATO
RASUVO®
MTX
ABITREXATE®
4-AMINO-10-METHYLFOLIC ACID
N-[4-[[(2,4-DIAMINO-6-PTERIDINYL)METHYL]METHYLAMINO]BENZOYL]-L-GLUTAMIC ACID
METHOTREXATUM
4-AMINO-N(10)-METHYLPTEROYLGLUTAMIC ACID
METHOTREXAT
MÉTHOTREXATE
chemidplus:59-05-2
chembl:CHEMBL34259
pubchem.compound:126941
drugbank:00563
rxcui:6851

Drug Info:

Drug Categories	folic acid antagonists
Drug Categories	antirheumatic agents
Drug Categories	abortifacient agents, nonsteroidal
FDA Approval	approved
Drug Class	Small molecule
Drug Indications	DMARD
Drug Categories	agents causing muscle toxicity
Drug Categories	cardiotoxic antineoplastic agents
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 substrates
Drug Categories	dermatologicals
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	drugs that are mainly renally excreted
Drug Categories	folic acid analogues
Drug Categories	hepatotoxic agents
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	narrow therapeutic index drugs
Drug Categories	nephrotoxic agents
Drug Categories	oat1/slc22a6 inhibitors
Drug Categories	oat3/slc22a8 inhibitors
Drug Categories	oat3/slc22a8 substrates
Drug Categories	oatp1b3 substrates
Drug Categories	p-glycoprotein substrates
Drug Categories	photosensitizing agents

(10 More Sources)

Publications:

Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer
Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer
Kurzawski M et al., 2016, ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients., Pharmacogenomics
James HM et al., 2008, Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis., J Rheumatol
Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J
Muralidharan N et al., 2016, ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis., Pharmacogenomics
Salazar J et al., 2014, Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?, Pharmacogenomics
Lima A et al., 2016, Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome., Pharmacogenomics
López-Rodríguez R et al., 2018, Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis., Pharmacogenomics J
Wessels JA et al., 2006, Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis., Arthritis Rheum
Iannaccone CK et al., 2011, Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study., Rheumatology (Oxford)
Dervieux T et al., 2004, Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis., Arthritis Rheum
Allegra et al., 1985, Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates., Proc. Natl. Acad. Sci. U.S.A.
Inoue K et al., 2014, Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy., Drug Metab Pharmacokinet
Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood
Serra et al., 2004, Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells., Ann. Oncol.
Wani et al., 1994, Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells., Cancer Res.
Domin et al., 1983, Establishment of dihydrofolate reductase-increased human cell lines and relationship between dihydrofolate reductase levels and gene copy., Cancer Res.
Selassie et al., 1982, A comparison of the inhibition of growth of methotrexate-resistant and -sensitive leukemia cells in culture by triazines. Evidence for a new mechanism of cell resistance to methotrexate., J. Med. Chem.
Cavalcanti et al., 1992, Simultaneous changes in various mechanisms that mediate the cell incorporation of folate compounds account for low levels of resistance to methotrexate., Cell Biochem. Funct.
Uga et al., 2006, A new mechanism of methotrexate action revealed by target screening with affinity beads., Mol. Pharmacol.
Ongaro A et al., 2009, Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival., Haematologica
Jabeen S et al., 2015, Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate., Pharmacogenomics J
Kaufman et al., 1981, Amplification and loss of dihydrofolate reductase genes in a Chinese hamster ovary cell line., Mol. Cell. Biol.
Sharma S et al., 2009, Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians., Pharmacogenet Genomics
Thompson et al., 1992, Assay for expression of methotrexate-resistant dihydrofolate reductase activity in the presence of drug-sensitive enzyme., J Pharmacol Toxicol Methods
Neef et al., 1976, Interaction of 1,N6-ethenoadenine derivatives of triphosphopyridine and reduced triphosphopyridine nucleotides with dihydrofolate reductase from amethopterin-resistant L1210 cells., Biochemistry
Hänggi et al., 1976, Altered regulation of the rate of synthesis of dihydrofolate reductase in methotrexate-resistant hamster cells., J. Biol. Chem.
Totani et al., 2006, High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates., Bioorg. Med. Chem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Salazar J et al., 2012, Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia., Pharmacogenomics J
Assaraf, 2007, Molecular basis of antifolate resistance., Cancer Metastasis Rev.
Bennett et al., 2006, Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate., Proc. Natl. Acad. Sci. U.S.A.
Al-Rashood et al., 2006, Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs., Bioorg. Med. Chem.
Al-Shakfa F et al., 2009, DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia., Clin Cancer Res
Kodidela S et al., 2015, Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317A>G) and rs442767 (-680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia., Eur J Clin Pharmacol
Costea et al., 2003, The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia., Pharmacogenetics
Costea I et al., 2006, Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia., Haematologica
Yang JJ et al., 2012, Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia., Blood
Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Chen et al., 2002, Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system., Cancer Res.
Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
Lopez-Lopez E et al., 2013, Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia., Pharmacogenet Genomics
den Hoed MA et al., 2015, Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia., Pharmacogenomics J
Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer
Stocco G et al., 2012, PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity., Hum Mol Genet
Wollina et al., 1985, [Alpha 1-fetoprotein--a marker of potential PUVA side-effects in psoriasis?]., Z. Hautkr.
Cheng Q et al., 2004, A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells., Pharmacogenetics
Jekic B et al., 2013, Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients., Eur J Clin Pharmacol
van der Straaten RJ et al., 2007, Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients., Pharmacogenomics
Hayashi H et al., 2009, Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis., J Clin Pharm Ther
Garcia-Bournissen F et al., 2007, Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene., Leuk Res
Dervieux T et al., 2004, Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis., Pharmacogenetics
Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
Yoshida et al., 2004, Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts., Prostaglandins Leukot. Essent. Fatty Acids
Krajinovic M et al., 2005, Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis., Pharmacogenomics J
Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.
Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
Ansari M et al., 2012, Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia., Pharmacogenomics J
Indhumathi S et al., 2017, Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis., Eur J Clin Pharmacol
Stamp LK et al., 2010, Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate., Pharmacogenet Genomics
de Jonge R et al., 2005, Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia., Blood
Dorababu P et al., 2012, Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL., Pharmacogenomics
Huang L et al., 2008, Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia., Leukemia
Yanagimachi M et al., 2013, Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy., Int J Hematol
Simon N et al., 2013, Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy., Pharmacogenomics J
Ranganathan P et al., 2008, Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis., J Rheumatol
Foell et al., 2004, Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations., Arthritis Rheum.
Chen Y et al., 2017, Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis., Pharmacogenomics
Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther
Pohl et al., 2003, High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin., J. Clin. Oncol.
Foell et al., 2004, Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?, Ann. Rheum. Dis.
Pinto et al., 1996, Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells., Clin. Cancer Res.
Lecomte et al., 2000, Maurotoxin and the Kv1.1 channel: voltage-dependent binding upon enantiomerization of the scorpion toxin disulfide bridge Cys31-Cys34., J. Pept. Res.
Hareedy MS et al., 2015, Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients., Pharmacogenomics
Dervieux T et al., 2009, Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis., Pharmacogenet Genomics
Imanishi et al., 2007, Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma., J. Hum. Genet.
Lima A et al., 2015, Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?, Int J Mol Sci
López-Rodríguez R et al., 2018, Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis., Sci Rep
Warren RB et al., 2008, Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis., J Invest Dermatol
Yang JJ et al., 2009, Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia., JAMA
Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
Plant D et al., 2012, A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register., Pharmacogenomics J
Hider SL et al., 2008, Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX., Rheumatology (Oxford)
Xian et al., 2000, Increased expression of HGF and c-met in rat small intestine during recovery from methotrexate-induced mucositis., Br. J. Cancer
Liu SG et al., 2017, Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia., Oncotarget
Tirona RG et al., 2001, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans., J Biol Chem
Goričar K et al., 2014, Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma., Pharmacogenet Genomics
Ramsey LB et al., 2013, Genome-wide study of methotrexate clearance replicates SLCO1B1., Blood
Treviño LR et al., 2009, Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects., J Clin Oncol
Csordas K et al., 2014, Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia., Br J Haematol
Eldem İ et al., 2018, SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy., J Pediatr Hematol Oncol
Moriyama T et al., 2015, Inherited genetic variation in childhood acute lymphoblastic leukemia., Blood
Chen et al., 2006, Nuclear receptor interactions in methotrexate induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1)., J. Biochem. Mol. Toxicol.
Majorczyk E et al., 2014, Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment., BMC Musculoskelet Disord
Kohli et al., 1990, Expression and amplification of cloned rat liver tyrosine aminotransferase in nonhepatic cells., J. Cell. Physiol.
Lora et al., 2004, Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells., Eur. J. Biochem.
Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
Kooloos WM et al., 2010, Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis., Pharmacogenomics
Thussbas C et al., 2006, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer., J Clin Oncol
López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Seitz et al., 1998, Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes., Arthritis Rheum.
Krajinovic M et al., 2005, Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL., Pharmacogenomics
Baggott et al., 1986, Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide., Biochem. J.
Rizzo R et al., 2006, HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis., Pharmacogenet Genomics
Stamp LK et al., 2009, Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis., Ann Rheum Dis
Barbisan F et al., 2014, Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism., PLoS One
Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Morita et al., The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production., Scand. J. Rheumatol.
Tahara et al., 2004, Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil., Oncol. Rep.
Yazici et al., 2005, The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment., Arch. Dermatol. Res.
Hawkes et al., 1994, The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis., J. Rheumatol.
Hall et al., Long-term exposure to methotrexate induces immunophenotypic changes, decreased methotrexate uptake and increased dihydrofolate gene copy number in Jurkat T cells., Int. J. Immunopharmacol.
Seitz et al., 1996, Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate., J. Rheumatol.
Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud
Abida et al., 2002, Receptor-dependence of the transcription read-out in a small-molecule three-hybrid system., Chembiochem
Nakagawa H et al., 2008, Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2., Biochem J
Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

METHOTREXATE AMPD1

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20386493 27217051 29520081 16947783 27992285

Sources:
PharmGKB
METHOTREXATE ATIC

Interaction Score: 1.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
27885916 18322994 27217051 26799664 25084201 27676277 29520081 16947783 20847201 15457444 3860829 24284432

Sources:
NCI PharmGKB DrugBank
METHOTREXATE SPECC1L

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18539621

Sources:
PharmGKB
METHOTREXATE SLAMF1

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16882589

Sources:
NCI
METHOTREXATE KIR2DS4

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25069714

Sources:
PharmGKB
METHOTREXATE SLC22A9

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
METHOTREXATE PTPRM

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24583629

Sources:
PharmGKB
METHOTREXATE ADORA2A-AS1

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27399166

Sources:
PharmGKB
METHOTREXATE MTRR

Interaction Score: 0.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16013960 29743634 15797993 18368069

Sources:
PharmGKB
METHOTREXATE ITPA

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26237184 19858780 27217051 29520081 16947783

Sources:
PharmGKB
METHOTREXATE GGH

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15284538 22763757 17286537 19827168 16999998 15564880

Sources:
PharmGKB
METHOTREXATE HLA-G

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16906016 19088262

Sources:
PharmGKB
METHOTREXATE ARID5B

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24712521

Sources:
PharmGKB
METHOTREXATE TNFAIP3

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20921970

Sources:
PharmGKB
METHOTREXATE NALCN

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19176441

Sources:
PharmGKB
METHOTREXATE PACSIN2

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22846425

Sources:
PharmGKB
METHOTREXATE DHFR

Interaction Score: 0.48

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name VIBEX MTX

Specific Action of the Ligand Inhibition

PMIDs:
14679136 8162600 6831441 7057421 1533575 25084201 16936229 19648163 25778468 7346712 19902562 1489988 9129 944698 16647263 11752352 21747412 17333344 17130456 24284432 16971132 19861437 26335211

Sources:
NCI PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
METHOTREXATE SLC46A1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21317831

Sources:
PharmGKB TTD
METHOTREXATE FOXP3

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28444425

Sources:
PharmGKB
METHOTREXATE SHMT1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20386493 18322994 15797993 22838948 18368069

Sources:
PharmGKB
METHOTREXATE ENOSF1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18322994 16130010

Sources:
PharmGKB
METHOTREXATE IL1RN

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8877917

Sources:
NCI
METHOTREXATE ICAM3

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16215763

Sources:
NCI
METHOTREXATE ATP5E

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26307125

Sources:
PharmGKB
METHOTREXATE SLC16A7

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METHOTREXATE KLRD1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26453102

Sources:
PharmGKB
METHOTREXATE FPGS

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19902562

Sources:
PharmGKB
METHOTREXATE S100A8

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14722212

Sources:
NCI
METHOTREXATE IKZF1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30044693

Sources:
CIViC
METHOTREXATE FOLH1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22838948 9816319

Sources:
NCI PharmGKB
METHOTREXATE SOD2

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25330300

Sources:
PharmGKB
METHOTREXATE DROSHA

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24614921

Sources:
PharmGKB
METHOTREXATE SLCO1A2

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21317831

Sources:
PharmGKB
METHOTREXATE SLC22A11

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26086825

Sources:
PharmGKB
METHOTREXATE SULT2A1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17163485

Sources:
NCI
METHOTREXATE S100A12

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15077313

Sources:
NCI
METHOTREXATE HLA-E

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METHOTREXATE UGT1A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE HSPB2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15519494

Sources:
NCI
METHOTREXATE UGT1A7

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE TPM3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8509220

Sources:
NCI
METHOTREXATE SLCO1B1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28525903 11477075 25098908 23233662 19901119 21317831 23652803 24712521 29683944 25999454

Sources:
PharmGKB CIViC
METHOTREXATE ABCC4

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12036927 25502615 23222202 25348617

Sources:
NCI PharmGKB
METHOTREXATE UGT1A10

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE LINC00251

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
METHOTREXATE FOLR1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21317831

Sources:
PharmGKB
METHOTREXATE BMP7

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
METHOTREXATE DOK5

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
METHOTREXATE CCND1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12972956 16870553

Sources:
NCI PharmGKB
METHOTREXATE SLC22A8

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615 21317831

Sources:
PharmGKB
METHOTREXATE SLC19A1

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
TTD GuideToPharmacology
METHOTREXATE UGT1A8

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE ABCC2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27217051 24241962 29791011 23069858 25502615 23222202 21317831 18381794

Sources:
PharmGKB
METHOTREXATE HLA-C

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28444425

Sources:
PharmGKB
METHOTREXATE CDKN1B

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14512390

Sources:
NCI
METHOTREXATE AFP

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2581382

Sources:
NCI
METHOTREXATE ABCC3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22016816 21317831 21606946

Sources:
PharmGKB
METHOTREXATE GATA3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24141364

Sources:
PharmGKB
METHOTREXATE TAT

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1967611

Sources:
NCI
METHOTREXATE UGT1A6

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE UGT1A3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE UGT1A4

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE PYGL

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007406

Sources:
PharmGKB
METHOTREXATE KCNA1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10727107

Sources:
NCI
METHOTREXATE ABCG2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20386493 18237272 27217051 29791011 25778468 18256692 21317831

Sources:
PharmGKB
METHOTREXATE E2F1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14654896

Sources:
NCI
METHOTREXATE HGF

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10732770

Sources:
NCI
METHOTREXATE NOTCH1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Methotrexate

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB
METHOTREXATE NCOA3

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE UGT1A9

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE TLR4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20136356

Sources:
PharmGKB
METHOTREXATE ABCC1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26086825 29743634 18256692 21317831

Sources:
PharmGKB
METHOTREXATE ADA

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2431676

Sources:
NCI
METHOTREXATE RB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Methotrexate

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB
METHOTREXATE TYMS

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
23652803 24284432

Sources:
CIViC DrugBank
METHOTREXATE GSTM1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17180579

Sources:
NCI
METHOTREXATE NOS3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19671875 25545243 29938344

Sources:
PharmGKB
METHOTREXATE SLCO1B3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21317831

Sources:
PharmGKB
METHOTREXATE FCGR3B

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9811059

Sources:
NCI
METHOTREXATE FGFR4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16822847

Sources:
PharmGKB
METHOTREXATE ALOX5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8151588

Sources:
NCI
METHOTREXATE BIRC5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15670151

Sources:
NCI
METHOTREXATE IL2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9669212

Sources:
NCI
METHOTREXATE UGT1A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
METHOTREXATE ADORA2A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27399166 18539621

Sources:
PharmGKB
METHOTREXATE BAX

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11237386

Sources:
NCI
METHOTREXATE NTRK1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8509220

Sources:
NCI
METHOTREXATE GLS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15511236

Sources:
NCI
METHOTREXATE FLT3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin

Indication/Tumor Type acute promyelocytic leukemia

Response Type sensitive

PMIDs:
27626069

Sources:
JAX-CKB
METHOTREXATE NR3C1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12210990

Sources:
NCI
METHOTREXATE TARDBP

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE MPHOSPH8

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE TP53

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17363498

Sources:
DTC CIViC
METHOTREXATE POLH

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE APEX1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE PPARG

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE POLB

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE CYP2C9

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
METHOTREXATE POLI

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE CYP2C19

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
METHOTREXATE CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
METHOTREXATE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
METHOTREXATE IDH1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE HSD17B10

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
METHOTREXATE VDR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METHOTREXATE EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00563

Version: 5.1.7

Alternate Names:

Rheumatrex Drug Brand

METHOTREXATE DrugBank Drug Name

59-05-2 CAS Number

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories abortifacient agents

Publications:

Uga et al., 2006, A new mechanism of methotrexate action revealed by target screening with affinity beads., Mol. Pharmacol.

Totani et al., 2006, High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates., Bioorg. Med. Chem.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

TdgClinicalTrial: METHOTREXATE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications DMARD

Drug Class Small molecule

FDA Approval approved

Publications:

NCI: METHOTREXATE

Version: 14-September-2017

Alternate Names:

C642 NCI drug code

Drug Info:

Publications:

Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer

Gorczyca et al., 1992, Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide., Cancer Res.

Peters et al., 1993, Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism., Int. J. Cancer

NCI: MTX

Version: 14-September-2017

Alternate Names:

C642 NCI drug code

Drug Info:

Publications:

Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.

Foell et al., 2004, Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations., Arthritis Rheum.

Tahara et al., 2004, Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil., Oncol. Rep.

NCI: AMETHOPTERIN

Version: 14-September-2017

Alternate Names:

C642 NCI drug code

Drug Info:

Publications:

Neef et al., 1976, Interaction of 1,N6-ethenoadenine derivatives of triphosphopyridine and reduced triphosphopyridine nucleotides with dihydrofolate reductase from amethopterin-resistant L1210 cells., Biochemistry

DTC: METHOTREXATE
- Version: 02-September-2020
Alternate Names:

CHEMBL34259 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

JAX-CKB: Methotrexate

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

Bochtler et al., 2016, Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia., Cold Spring Harb Mol Case Stud

PharmGKB: methotrexate

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tsujimoto S et al., 2016, Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies., Pediatr Blood Cancer

Senapati S et al., 2014, Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation., Pharmacogenet Genomics

Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine

CIViC: METHOTREXATE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther

Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood

TTD: Methotrexate
- Version: 2020.06.01
Alternate Names:

D0SV8E TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178101517
- Version: 29-September-2020
Alternate Names:

METHOTREXATE GuideToPharmacology Ligand Name

Drug Info:

Publications:
DTC: TCMDC-125488
- Version: 02-September-2020
Alternate Names:

CHEMBL426 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL34259
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL34259
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	VIBEX MTX
Specific Action of the Ligand	Inhibition

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

combination therapy	Ribociclib + Methotrexate
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	decreased response

combination therapy	Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin
Indication/Tumor Type	acute promyelocytic leukemia
Response Type	sensitive

Rheumatrex	Drug Brand
METHOTREXATE	DrugBank Drug Name
59-05-2	CAS Number

Drug Type	small molecule
Drug Groups	approved
Drug Categories	abortifacient agents

METHOTREXATE Drug Record

METHOTREXATE chembl:CHEMBL34259 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20386493 27217051 29520081 16947783 27992285

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 27885916 18322994 27217051 26799664 25084201 27676277 29520081 16947783 20847201 15457444 3860829 24284432

Sources: NCI PharmGKB DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18539621

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16882589

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25069714

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24583629

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27399166

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16013960 29743634 15797993 18368069

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26237184 19858780 27217051 29520081 16947783

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15284538 22763757 17286537 19827168 16999998 15564880

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16906016 19088262

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24712521

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20921970

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19176441

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22846425

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name VIBEX MTX Specific Action of the Ligand Inhibition

PMIDs: 14679136 8162600 6831441 7057421 1533575 25084201 16936229 19648163 25778468 7346712 19902562 1489988 9129 944698 16647263 11752352 21747412 17333344 17130456 24284432 16971132 19861437 26335211

Sources: NCI PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21317831

Sources: PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28444425

Interaction Types & Directionality:

n/a

PMIDs:
20386493 27217051 29520081 16947783 27992285

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
27885916 18322994 27217051 26799664 25084201 27676277 29520081 16947783 20847201 15457444 3860829 24284432

Sources:
NCI PharmGKB DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
18539621

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16882589

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25069714

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24583629

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27399166

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16013960 29743634 15797993 18368069

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26237184 19858780 27217051 29520081 16947783

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15284538 22763757 17286537 19827168 16999998 15564880

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16906016 19088262

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24712521

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20921970

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19176441

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22846425

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name VIBEX MTX

Specific Action of the Ligand Inhibition

PMIDs:
14679136 8162600 6831441 7057421 1533575 25084201 16936229 19648163 25778468 7346712 19902562 1489988 9129 944698 16647263 11752352 21747412 17333344 17130456 24284432 16971132 19861437 26335211

Sources:
NCI PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
21317831

Sources:
PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
28444425

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20386493 18322994 15797993 22838948 18368069

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18322994 16130010

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8877917

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16215763

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
26307125

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26453102

Sources:
PharmGKB

Interaction Types & Directionality:

n/a